Medtronic 경영진

경영진 기준 점검 3/4

Medtronic CEO는 Geoff Martha, Apr2020 에 임명되었습니다 의 임기는 5.5 년입니다. 총 연간 보상은 $21.24M, 6.4% 급여 및 93.6% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $12.71M 가치에 해당하는 회사 주식의 0.01% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.9 년과 6.3 년입니다.

핵심 정보

Geoff Martha

최고경영자

US$21.2m

총 보수

CEO 급여 비율	6.36%
CEO 재임 기간	5.5yrs
CEO 지분 보유율	0.01%
경영진 평균 재임 기간	2.9yrs
이사회 평균 재임 기간	6.3yrs

최근 경영진 업데이트

Recent updates

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Feb 17Strengths and Competitive Advantages:Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and

Medtronic (NYSE:MDT) Has More To Do To Multiply In Value Going Forward

Feb 17

Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release

Feb 15

Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock

Feb 07

We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt

Jan 20

Medtronic: A Dividend Aristocrat That's Poised To Pop

Jan 06

Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects

Jan 06

Medtronic Stock Is Still A Great "Buy"

Dec 26

Medtronic (NYSE:MDT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Dec 03

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

Nov 19

Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns

Nov 08

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

Oct 31

Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?

Oct 13

Medtronic: Undervalued Dividend Aristocrat With High Margins

Oct 10

Medtronic: An Undervalued Stock With Durable Competitive Advantages

Sep 16

Medtronic: Is The Company Back?

Aug 26

Medtronic: Still A Buy Before Earnings

Aug 17

Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential

Jul 16

CEO 보수 분석

Geoff Martha의 보수는 Medtronic의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Jul 25 2025	n/a	n/a	US$5b
Apr 25 2025	US$21m	US$1m	US$5b
Jan 24 2025	n/a	n/a	US$4b
Oct 25 2024	n/a	n/a	US$4b
Jul 26 2024	n/a	n/a	US$4b
Apr 26 2024	US$20m	US$1m	US$4b
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

보상 대 시장: Geoff의 총 보수(USD21.24M)는 US 시장에서 비슷한 규모 기업의 평균(USD13.36M)보다 높습니다.

보상과 수익: Geoff의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Geoff Martha (55 yo)

5.5yrs

재임 기간

US$21,240,058

보수

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Independent Directo...

리더십 팀

이름	직위	재임 기간	보수	지분
Geoffrey Martha	Chairman of the Board & CEO	5.5yrs	US$21.24m	0.010% $ 12.7m
Thierry Pieton	Executive VP & CFO	less than a year	US$5.21m	0% $ 0
Gary Corona	Senior VP of Corporate Finance	less than a year	US$4.04m	0.00061% $ 747.1k
Brett Wall	Executive VP & President of Neuroscience Portfolio	5.9yrs	US$8.12m	0.0016% $ 1.9m
Gregory Smith	Executive Vice President of Enterprise Operations	4.5yrs	US$8.08m	0.0025% $ 3.1m
Mark Ploof	Senior Vice President of Global Operations and Business Services	9yrs	데이터 없음	데이터 없음
Denise Blomquist	VP, Global Controller & Chief Accounting Officer	less than a year	데이터 없음	0.00034% $ 416.4k
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	2.3yrs	데이터 없음	데이터 없음
Laura Mauri	Senior VP and Chief Scientific & Medical Officer	3.5yrs	데이터 없음	데이터 없음
Ryan Weispfenning	VP & Head of Investor Relations	10.3yrs	데이터 없음	데이터 없음
Michelle Quinn	Executive VP	less than a year	데이터 없음	데이터 없음
Matthew Walter	Senior VP & Chief Human Resources Officer	2.3yrs	데이터 없음	0.0019% $ 2.3m

2.9yrs

평균 재임 기간

56yo

평균 나이

경험이 풍부한 관리: MDT의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.9 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Geoffrey Martha	Chairman of the Board & CEO	5.9yrs	US$21.24m	0.010% $ 12.7m
Scott Donnelly	Independent Director	12.8yrs	US$365.06k	0.0013% $ 1.6m
Kendall Powell	Independent Director	18.8yrs	US$350.06k	0.0017% $ 2.0m
Randall Hogan	Independent Director	10.8yrs	US$385.06k	0.0035% $ 4.3m
Craig Arnold	Lead Independent Director	10.8yrs	US$410.06k	0.0030% $ 3.6m
Andrea Goldsmith	Independent Director	6.6yrs	US$370.06k	0.00064% $ 783.8k
Elizabeth Nabel	Independent Director	11.8yrs	US$370.06k	0.0012% $ 1.5m
Lidia Fonseca	Independent Director	3.3yrs	US$350.06k	0.00028% $ 342.9k
Kevin Lofton	Independent Director	5.1yrs	US$370.06k	0.00047% $ 575.6k
Gregory Lewis	Independent Director	2.3yrs	US$370.28k	0.00013% $ 159.2k
John Groetelaars	Independent Director	less than a year	데이터 없음	데이터 없음
Joon Lee	Independent Director	less than a year	데이터 없음	데이터 없음

6.3yrs

평균 재임 기간

63yo

평균 나이

경험이 풍부한 이사회: MDT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/03 04:30
종가	2025/10/03 00:00
수익	2025/07/25
연간 수익	2025/04/25

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Medtronic plc는 67명의 분석가가 다루고 있습니다. 이 중 31명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Kadambari Daptardar	Accountability Research Corporation
Harshit Gupta	Accountability Research Corporation
David Toung	Argus Research Company

Medtronic 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Medtronic plc Announces Board Appointments

Medtronic plc, Annual General Meeting, Oct 16, 2025

Chairman of the Board & CEO exercised options and sold US$3.9m worth of stock

Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed, Effective July 14, 2025

Medtronic plc Appoints Dr. Joon Lee as A New Director and Member of Science and Technology Committee and the Compensation and Talent Committee, Effective as of June 18, 2025

Insider notifies of intention to sell stock

Recent updates

Medtronic: FY26 Outlook Strengthened By New Product Launches

Medtronic Secures FDA Approval for the Altaviva Device

Upcoming dividend of US$0.71 per share

Medtronic Initiates Global Pivotal Study of Cardiac Pacing in A New Patient Population

Medtronic's (NYSE:MDT) Solid Earnings Are Supported By Other Strong Factors

FDA Clears MiniMed 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Medtronic plc Announces Board Appointments

Fourth quarter dividend of US$0.71 announced

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2026, Payable on October 17, 2025

Medtronic plc, Annual General Meeting, Oct 16, 2025

Chairman of the Board & CEO exercised options and sold US$3.9m worth of stock

Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed, Effective July 14, 2025

Medtronic's (NYSE:MDT) Returns On Capital Are Heading Higher

Medtronic plc Appoints Dr. Joon Lee as A New Director and Member of Science and Technology Committee and the Compensation and Talent Committee, Effective as of June 18, 2025

Full year 2025 earnings: EPS misses analyst expectations

Upcoming dividend of US$0.71 per share

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Insider notifies of intention to sell stock

Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71

Fourth quarter dividend increased to US$0.71

Full year 2025 earnings: EPS misses analyst expectations

Medtronic plc Announces Cash Dividend for the First Quarter of Fiscal Year 2026, Payable on July 11, 2025

Medtronic plc Provides Earnings Guidance for the Fiscal Year 2026

Medtronic Expand URO U.S. Clinical Trial Meet Safety and Effectiveness Primary Endpoints for Hugo™ Robotic-Assisted Surgery System

Medtronic plc Receives FDA Approval for Smallest-Diameter, Lumenless Defibrillation Lead, the Omniasecure™ Lead and Announces Investigational Clinical Study Results

Medtronic plc Submits 510(K) Applications to U.S. Food and Drug Administration Seeking Clearance for Interoperable Pump

Medtronic: One Of The Best Times To Buy

Medtronic plc Announces U.S. Food and Drug Administration Approval for the Simplera Sync Sensor for Use with the MiniMed 780G System

Is Now An Opportune Moment To Examine Medtronic plc (NYSE:MDT)?

Medtronic plc Announces Late-Breaking Data on Five-Year Outcomes from the Evolut Low Risk Trial

Medtronic: A Great Business, But With Low Growth

Upcoming dividend of US$0.70 per share

Medtronic plc Announces Executive Changes

Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy

Medtronic plc Releases the Two-Year Results of the SMall Annuli Randomized To Evolut or SAPIEN Trial

Third quarter dividend of US$0.70 announced

Medtronic plc Announces Cash Dividend for Fourth Quarter of Fiscal Year 2025, Payable on April 11, 2025

Medtronic Earns U.S. FDA Approval for the World's First Adaptive Deep Brain Stimulation System for People with Parkinson's

Third quarter 2025 earnings: EPS misses analyst expectations

Medtronic plc Re-Iterates Earnings Guidance for the Full Year 2025

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Medtronic (NYSE:MDT) Has More To Do To Multiply In Value Going Forward

Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release

Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock

Medtronic plc to Report Q2, 2026 Results on Nov 18, 2025

Medtronic plc to Report Q1, 2026 Results on Aug 19, 2025

Insider notifies of intention to sell stock

Now 20% undervalued after recent price drop

Medtronic plc Announces Chief Financial Officer Changes, Effective March 3, 2025

We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt

Medtronic Announces CMS National Coverage Analysis for Symplicity™ Spyral Renal Denervation System

Medtronic: A Dividend Aristocrat That's Poised To Pop

Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects

Medtronic Stock Is Still A Great "Buy"

Upcoming dividend of US$0.70 per share

Second quarter dividend of US$0.70 announced

Medtronic plc Announces Cash Dividend for Third Quarter of Fiscal Year 2025, Payable on January 10, 2025

Medtronic (NYSE:MDT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM

New minor risk - Earnings quality

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns

CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial

Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter

Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?

Medtronic: Undervalued Dividend Aristocrat With High Margins